Komori
M&A and Subsidiary Changes4571Nano Holdings,Inc.Pharmaceuticals

(Correction) Partial Correction to the Notice Regarding the Change in Subsidiary Status Resulting from Strategic Subsidiary NANO MRNA’s Acquisition of Shares in Luna RD株式会社 (Making It a Subsidiary)

In the disclosure concerning the acquisition of Luna RD株式会社 as a subsidiary dated 24 April 2026, the description of the contract execution date in the schedule section was corrected from “Share Transfer Agreement Execution Date” to “Investment Agreement Execution Date.” Both execution dates are 24 April 2026, and the date itself has not changed.

Worth reading
24Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

The document this correction applies to

Timely disclosure
Notice Regarding a Change in Subsidiaries Resulting from the Acquisition of Shares in Luna RD Co., Ltd. (Making It a Subsidiary) by Strategic Subsidiary NANO MRNA2026-04-24

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure24 April 2026

Notice Regarding a Change in Subsidiaries Resulting from the Acquisition of Shares in Luna RD Co., Ltd. (Making It a Subsidiary) by Strategic Subsidiary NANO MRNA

Open the original document
Corrected on the same dayCorrected on the same day as the original document (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-04-24
Location of correction (where in the original document)

4. Schedule (2) Share Transfer Agreement Execution Date / Investment Agreement Execution Date

Before correction

(2) Share Transfer Agreement Execution Date: 24 April 2026

After correction

(2) Investment Agreement Execution Date: 24 April 2026

ChangesCorrection to the name of the contract execution date
Reason for correction

Certain descriptions contained errors.

What was corrected and how
ItemDetails
Disclosure subject to correctionNotice Regarding a Change in Subsidiaries Resulting from the Acquisition of Shares in Luna RD Co., Ltd. (Making It a Subsidiary) by Strategic Subsidiary NANO MRNA
Original disclosure date24 April 2026
Location of correction4. Schedule (2) Share Transfer Agreement Execution Date / Investment Agreement Execution Date
Details of correction(2) Share Transfer Agreement Execution Date: 24 April 2026 → (2) Investment Agreement Execution Date: 24 April 2026
Reason for correctionCertain descriptions contained errors.
Items this document does not state (1)
Impact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that it was making the correction because part of the information in the disclosure published on 24 April 2026 was incorrect.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial Correction to the Notice Regarding the Change in Subsidiary Status Resulting from Strategic Subsidiary NANO MRNA’s Acquisition of Shares in Luna RD株式会社 (Making It a Subsidiary) | Nano Holdings,Inc. (4571) timely disclosure | Komori